ClinicalTrials.gg
CompletedNCT02891980Updated Jul 29, 2025

A Safety Trial to Test MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers

A Phase 1 interventional study of Ad26 Zaire Ebola Vaccine and MVA Multi-Filo Ebola Vaccine in Ebola Disease and Marburg Disease, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-29.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 1, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was Mar 2019, 7 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Hemorrhagic Fever, Ebola by National Institute of Allergy and Infectious Diseases (NIAID) — none open to participants now, none under way, none of them phase 3. Hemorrhagic Fever, Ebola · National Institute of Allergy and Infectious Diseases (NIAID).

Enrollment
7th of 17
65 · median 57
Started
2017
with 3 others
Phase 1
14 of 20
none open now
Registered
15th of 20
by date

Among the 20 studies in Hemorrhagic Fever, Ebola by National Institute of Allergy and Infectious Diseases (NIAID), this one is the 7th largest by enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2017, is one of 14 in phase 1, and was the 15th registered.

Hemorrhagic Fever, Ebola

104 studies on the registry are indexed under Hemorrhagic Fever, Ebola; 13 are open to participants now.

Browse Hemorrhagic Fever, Ebola studies →

Open to participants now

None of the 20 studies in Hemorrhagic Fever, Ebola by National Institute of Allergy and Infectious Diseases (NIAID) is open now. The open studies under Hemorrhagic Fever, Ebola, anywhere →

Who these studies take

Of the 4 Hemorrhagic Fever, Ebola studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; none take children under 18; 4 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies in Hemorrhagic Fever, Ebola by National Institute of Allergy and Infectious Diseases (NIAID) as a file.
02

Study summary

This is a Phase 1, double-blind, randomized trial to evaluate the safety and immunogenicity of two heterologous and two homologous prime-boost regimens using MVA-BN(R)-Filo and Ad26.ZEBOV administered in different sequences at Days 1 and 29 in healthy adult subjects aged 18 - 45 years. The study will evaluate the 'omics (transcriptomics, proteomics, lipidomics, metabolomics), antibodies for immunogenicity, CMI, ADCC, and plasmablast responses to MVA-BN(R)-Filo and Ad26.ZEBOV vaccines. The primary objectives of this study are: 1) To assess the safety and reactogenicity of each study group. 2) To assess responses to the study vaccination by study group after the first, second and third dose by transcriptomics. 3) To assess the peak antibody response to the study vaccination by study group to filovirus antigens.

Read the detailed description

This is a Phase 1, double-blind, randomized trial to evaluate the safety and immunogenicity of two heterologous and two homologous prime-boost regimens using MVA-BN(R)-Filo and Ad26.ZEBOV administered in different sequences at Days 1 and 29 in healthy adult subjects aged 18 - 45 years. The two heterologous prime-boost groups will also receive MVA-BN(R)-Filo at day 366. Sixty subjects will be randomized 1:1:1:1 to one of four study groups (15 per group). Subjects and study staff will be blinded to a subject's study vaccine assignment within study vaccination schedule (e.g., enrollment into Group 1 or 4 versus 2 or 3 will be known). The study will evaluate the 'omics (transcriptomics, proteomics, lipidomics, metabolomics), antibodies for immunogenicity, CMI, ADCC, and plasmablast responses to MVA-BN(R)-Filo and Ad26.ZEBOV vaccines. The primary objectives of this study are: 1) To assess the safety and reactogenicity of each study group. 2) To assess responses to the study vaccination by study group after the first, second and third dose by transcriptomics. 3) To assess the peak antibody response to the study vaccination by study group to filovirus antigens. Secondary objectives are: 1) To assess antigen-specific cell-mediated immune (CMI) responses to the study vaccination by study group. 2) To assess antibody-dependent cell-mediated cytotoxicity (ADCC) responses to the study vaccination by study group.

03

Conditions studied

  • Ebola Disease
  • Marburg Disease

Keywords

  • Ad26.ZEBOV
  • Ebola
  • Immunogenicity
  • Marburg
  • MVA-BN-Filo
  • Omics
  • Zaire
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must be able to read and provide consent after completing the process.
  2. Subject must be able to understand and comply with planned procedures.
  3. Subject must be a man or woman aged > / = 18 to \< / = 45 years.
  4. Subject must have a (BMI) > / = 18.5 and \< 35 kg/m\^2.
  5. Subject must be healthy on the basis of patient-reported medical history, physical examination, and the investigator's clinical judgment.
  6. Subject must have acceptable laboratory parameters* within 28 days of enrollment:

    • Note 1: If the following acceptable screening laboratory parameters** are out of range, repeat of screening tests is permitted once, provided there is an alternative explanation for the out of range value. The alternative explanation for the out of range value should be documented in the subject's source documents. The acceptable value for repeated screening tests must be available within the 28 days screening period.

Acceptable laboratory parameters include the following:

  • : women: > / = 11.5 g/dL; men > / = 12.5 g/dL
  • White blood cell (WBC) count: > 3.7 Thousand/uL but \< 10.9 Thousand/uL
  • > 1,500 cells/uL
  • : > 139 but \< 550 Thousand/uL
  • Urinalysis (clean urine sample)*: protein and blood \< 1+, glucose negative *Note: for women: in case of menstruation, urinalysis must be postponed, but a result should be available before Day 1.
  • (ALT) \< / = 1 x institutional
  • Serum creatinine \< / = 1 x institutional upper limit of normal
  • Troponin I \< / = 1 x institutional upper limit of normal
  • Fibrinogen > 140 mg/dL but \< / = 500 mg/dL
  • (PT) \< / = 1 x institutional upper limit of normal
  • Activated partial thromboplastin time (PTT) \< / = 1 x institutional upper limit of normal.
  • Negative test for .
  • Negative surface antigen and negative antibody to virus.

    • Note 2: Grade 1 abnormalities for laboratory tests other than those covered in this list are considered acceptable if not . If a Grade 2 or Grade 3 abnormality for lab tests other than those covered in this list is identified, repeating the screening tests is permitted once provided there is an alternative explanation for the out-of-range value. The alternative explanation for the out of range value should be documented in the subject's source documents.

      7. Women of must have a negative serum pregnancy test during screening and a negative urine pregnancy test immediately prior to each study vaccine administration.

      8. Women of childbearing potential must have an acceptable method of * from 28 days before the prime vaccination until at least 3 months after the last boost vaccination.

      *Acceptable methods of birth control include the following:

      a. Prescription oral contraceptives, contraceptive injections, intrauterine device (IUD), implants, vaginal ring, double-barrier method, contraceptive patch, male partner sterilization b. Abstinence (defined as refraining from heterosexual intercourse) c. If not heterosexually active at screening, must agree to practice adequate birth control measures if they become heterosexually active from the start of screening onwards until at least 3 months after the last boost vaccination.

      d. Women of non-childbearing potential, defined as (any age with amenorrhea for > / = 6 months and serum follicle-stimulating hormone [FSH] > 40 mIU/mL) or surgically sterile (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy), are not required to use the required birth control methods.

      9. Female subject agrees to not donate eggs (ova, oocytes) for the purposes of assisted reproduction from the start of screening onwards until at least 3 months after the last boost vaccination.

      10. Male subject who has not had a vasectomy and is sexually active with a woman of childbearing potential must agree to use an acceptable method* of birth control until at least 3 months after the last boost vaccination.

      *Acceptable methods of birth control include the following:

      1. A double-barrier method of birth control, such as condom and partner with occlusive cap (diaphragm, cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.
      2. In case the female partner is using an adequate method of birth control (see Inclusion Criterion #8), a single barrier method of birth control for the male subject is acceptable.

        11. Male subject must also agree not to donate sperm for the purposes of assisted reproduction from the start of screening onwards until at least 3 months after the last boost vaccination.

        12. Subject must be available and willing to participate for the duration of the study visits and follow-up (up to 19 months from enrollment).

        13. Subject must provide identification. 14. Subject must have a means to be contacted. 15. Subjects must have consistent access to the internet to perform electronic data entry.

Exclusion criteria

Exclusion Criteria:

  1. Has been vaccinated with an Ebola vaccine.
  2. Has been diagnosed with Ebola disease, or exposed to Ebola including travel to West Africa* in 2014-2016.

    • Note: West Africa includes but is not limited to the countries of Guinea, Liberia, Mali, and Sierra Leone. Subjects who anticipate traveling to epidemic Ebola areas before the end of the study will also be excluded from enrollment into the study.
  3. Known or suspected receipt of an adenovirus serotype 26 (Ad26)-based vaccine.
  4. Known or suspected receipt of any licensed or small pox (vaccinia)-based vaccine* *Note: Includes any MVA-based candidate vaccine (Imvamune or Imvanex), Dryvax, or Acam2000. Military history should be reviewed with potential subjects for receipt of vaccinia-based vaccine. The presence of a typical vaccinia scar should be considered exclusionary.
  5. Positive serology for (HIV)
  6. Positive surface antigen
  7. Positive antibody to virus (HCV)
  8. Known allergy or history of anaphylaxis or other serious adverse reactions to vaccines or vaccine products*.

    *Note: This includes a known allergy to egg, egg products and aminoglycosides or any of the constituents of the study vaccines [e.g., polysorbate 80, ethylenediaminetetraacetic acid (EDTA), L-histidine, tris (hydroxymethyl)-amino methane (THAM)).

  9. Has an acute illness or temperature > / = 38.0 degrees Celsius within the 3 days prior to Day 1.* *Note: Potential subjects can be rescheduled due to acute illness within the 28 day window between screening and enrollment. If acute illness prevents administration of vaccine within the 28 day screening window, the potential subject can be enrolled once the acute illness resolves after repeating safety laboratories and if the subject is otherwise eligible. The does not need to be repeated as it is not a safety laboratory and unlikely to change without clinical event in this age group of volunteers.
  10. Female subject is pregnant or breast-feeding, or planning to become pregnant while enrolled in the study or within 3 months after the last boost vaccination.
  11. A history of bleeding or clotting disorders.
  12. Any acute or chronic medical condition* that, in the opinion of the investigator, would preclude participation.

    • E.g., history of seizure disorders, disease, immunodeficiency, any spleen disease, active , active tuberculosis, asthma, or other systemic infections.
  13. History of malignancy other than squamous cell or basal cell skin cancer*, unless there has been surgical excision that is considered to have achieved cure.

    • Note: Subjects with a history of skin cancer must not be vaccinated at the previous tumor site.
  14. Prior organ and/or stem cell transplant.
  15. Major surgery (per the investigator's judgment) within the 4 weeks prior to study entry or planned major surgery through the course of the study.
  16. History of myocarditis, pericarditis, cardiomyopathy, or stroke, myocardial infarction, angina, coronary artery disease, congestive heart failure, or arrhythmia*.

    *Note: This includes any clinically significant arrhythmia requiring medication, treatment, or clinical follow-up.

  17. Electrocardiogram (ECG) with clinically significant findings,* or features that would interfere with the assessment of myocarditis/pericarditis.

    *Clinical significant findings include the following:

a. Conduction disturbance (complete left or complete right bundle branch block or nonspecific intraventricular conduction disturbance with QRS > / = 120 ms, PR interval > / = 210 ms, any second- or third-degree atrioventricular block, or prolongation of the corrected according to Bazett's formula [QTcB] [> 450 ms]) b. Significant repolarization (ST-segment or T-wave) abnormality. c. Significant atrial or ventricular arrhythmia; frequent atrial or ventricular ectopy (e.g., frequent premature atrial contractions, 2 premature ventricular contractions in a row).

d. ST-elevation consistent with ischemia or evidence of past or evolving myocardial infarction.

18. History of diabetes mellitus type 1 or type 2*, including cases controlled with diet alone.

  • Note: A history of isolated gestational diabetes is not an exclusion criterion. 19. Thyroidectomy or thyroid disease requiring medication during the last 12 months.

    20. Uncontrolled hypertension, defined as systolic blood pressure > / = 140 mmHg or diastolic blood pressure > / = 90 mmHg.*

  • Note: Vital signs must be normal by protocol toxicity grading scale or determined to be normal-variant by investigator. In the event of an abnormal heart rate or blood pressure due to physiological variation or activity, the subject may rest for 10 minutes in a quiet room, and then blood pressure and/or heart rate may be re-measured. Repeated vital signs may be used to determine eligibility.

    21. Received a licensed within 30 days prior to enrollment in this study, or plans to receive a licensed live vaccine within 30 days before or after each study vaccine.

    22. Received a licensed inactivated vaccine within 14 days prior to enrollment in this study, or plans to receive a licensed inactivated vaccine within 14 days before or after each study vaccine.

    23. Use of experimental therapeutic agents within 3 months from the start of screening.

    24. Current or planned participation in another clinical study during the study period.*

  • Note: Participation in an observational clinical study is allowed. 25. Receipt of blood products or immunoglobulin in the past 3 months. 26. Donation of a unit of blood within 8 weeks before Day 1 or plans to donate blood during participation in the study (from the start of screening onwards).

    27. Major psychiatric illness during the past 12 months that in the opinion of the investigator would preclude participation.

    28. Current or past abuse of recreational or narcotic drugs.*

  • Note: Urine will be tested only at screening to check for use of amphetamines, benzodiazepines, cocaine, and opioids.

    29. Current or past alcohol use judged by the investigator to potentially interfere with subject study adherence.

    30. History of chronic urticaria (recurrent hives). 31. Chronic or recurrent use of medications which modify host immune response (e.g., cancer chemotherapeutic agents, parenteral ).*

  • Note: This is defined as greater than 2 weeks duration within three months prior to vaccination or current use of medication:

    a. Permissible use during study include: corticosteroid nasal sprays for allergic rhinitis and low dose inhaled corticosteroids defined as \< 800 mcg/day of beclomethasone dipropionate CFC or equivalent.

    b. Topical steroid for mild uncomplicated dermatitis such as poison ivy or contact dermatitis should be completed before study.

    c. Oral/parenteral corticosteroids given for non-chronic conditions not expected to recur are permissible if the length of therapy was \< / = 14 days with completion at least 30 days prior to enrollment.

    32. Subject who cannot communicate reliably with the investigator. 33. Subject who, in the opinion of the investigator, is unlikely to adhere to the requirements of the study.

    34. Any condition that, in the opinion of the investigator, might interfere with assessing the study objectives.

    35. Personnel involved in the study*.

  • Note: This includes the Principal Investigator (PI), sub-Investigators listed in Form FDA 1572 or Investigator of Record Form, all staff who are paid entirely or partially by/through the OCRR contract for the trial, and staff who are supervised by the PI or sub-Investigators.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Group 2

    MVA-BN®-Filo Day 1, Ad26.ZEBOV Day 29 and MVA-BN®-Filo Day 366

    Biological: Ad26 Zaire Ebola Vaccine · Biological: MVA Multi-Filo Ebola Vaccine

  • Experimental
    Group 3

    Ad26.ZEBOV Day 1, MVA-BN®-Filo Day 29 and MVA-BN®-Filo Day 366

    Biological: Ad26 Zaire Ebola Vaccine · Biological: MVA Multi-Filo Ebola Vaccine

  • Experimental
    Group 4

    Ad26.ZEBOV Day 1, Ad26.ZEBOV Day 29

    Biological: Ad26 Zaire Ebola Vaccine

  • Experimental
    Group1

    MVA-BN®-Filo Day 1 and MVA-BN®-Filo Day 29

    Biological: MVA Multi-Filo Ebola Vaccine

Interventions

  • BiologicalAd26 Zaire Ebola Vaccine

    A recombinant adenovirus vector comprising a polynucleotide encoding a filovirus antigenic protein, wherein the recombinant adenovirus vector comprises an adenovirus 26 capsid protein.

  • BiologicalMVA Multi-Filo Ebola Vaccine

    A multivalent MVA-BN Filovirus vaccine, designed to protect against Ebola Zaire, Ebola Sudan and Marburg virus.

06

What researchers measure

Primary outcomes

  1. Determine the differential expression from baseline in mRNA after each study vaccination by study group

    Time frame: Screening and Days 1, 2, 4, 8, 15, 29, 30, 32, 36, 43, and 57 for Groups 1 and 4; additionally Days 366, 367, 369, 373, 380, 394, and 546 for Groups 2 and 3.

  2. Determine the number of subjects with a vaccine-related serious adverse event (SAE) from the time of first study vaccination by study group through the duration of the study

    Time frame: Day 1 through Day 366 in Groups 1 and 4; Day 1 through Day 546 in Groups 2 and 3

  3. Determine the number of subjects with a vaccine-related unsolicited adverse event (AE) from the time of each study vaccination by study group

    Time frame: Day 1 through Day 29

  4. Determine the number of subjects with solicited local and systemic reactogenicity events from the time of study vaccination by study group.

    Time frame: Day 1 through Day 8

  5. Determine the peak antibody response against filovirus glycoproteins (GPs) for each study group

    Time frame: Days 1, 15, 29, 36, 43, 57, 209, and 366 for Groups 1 and 4; additionally Days 369, 373, 380, 394, 546 for Groups 2 and 3.

Secondary outcomes

  1. Determine the change in CMI response from baseline against filovirus antigen using peptide pools and measurement by intracellular cytokine staining (ICS) in each of the study groups

    Time frame: Days 1, 15, 29, 36, 43, 57, 209, and 366 in Groups 1 and 4; additionally Days 369, 373, 380, 394, and 546 in Groups 2 and 3.

  2. Determine the change in the ADCC from baseline in each of the study groups

    Time frame: Days 1, 15, 29, 36, 43, 57, 209, and 366 for Groups 1 and 4; additionally Days 373, 380, 394, and 546 for Groups 2 and 3.

07

Study locations

1 site
  • Emory University School of Medicine
    Atlanta, Georgia 30322-1014, United States
08

References and documents

Publications

  • Rostad CA, Yildirim I, Kao C, Yi J, Kamidani S, Peters E, Stephens K, Gibson T, Hsiao HM, Singh K, Spearman P, McCracken C, Agbakoba V, Tomashek KM, Goll JB, Gelber CE, Johnson RA, Lee S, Maner-Smith K, Bosinger S, Ortlund EA, Chen X, Anderson LJ, Wrammert J, Suthar M, Rouphael N, Anderson EJ. A Phase 1 randomized trial of homologous and heterologous filovirus vaccines with a late booster dose. NPJ Vaccines. 2024 Dec 23;9(1):255. doi: 10.1038/s41541-024-01042-4. PubMed 39715748 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Mar 2019, 23 months.

Of 16 phase 1 interventional studies under Hemorrhagic Fever, Ebola, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 23 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2016
First posted
Sep 8, 2016
StartActual
Mar 24, 2017
Primary completionActual
Mar 21, 2019
CompletionActual
Mar 21, 2019
Last update
Jul 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02891980
Responsible party
Sponsor
First posted
Sep 8, 2016
Start date
Mar 24, 2017
Primary completion
Mar 21, 2019
Completion
Mar 21, 2019
Last update
Jul 29, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion